<SEC-DOCUMENT>0000947871-25-000063.txt : 20250122
<SEC-HEADER>0000947871-25-000063.hdr.sgml : 20250122
<ACCEPTANCE-DATETIME>20250122161728
ACCESSION NUMBER:		0000947871-25-000063
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250122
DATE AS OF CHANGE:		20250122

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Outlook Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001649989
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				383982704
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			0930

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-89495
		FILM NUMBER:		25546178

	BUSINESS ADDRESS:	
		STREET 1:		111 S. WOOD AVENUE
		STREET 2:		UNIT #100
		CITY:			ISELIN
		STATE:			NJ
		ZIP:			08830
		BUSINESS PHONE:		6096193990

	MAIL ADDRESS:	
		STREET 1:		111 S. WOOD AVENUE
		STREET 2:		UNIT #100
		CITY:			ISELIN
		STATE:			NJ
		ZIP:			08830

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Oncobiologics, Inc.
		DATE OF NAME CHANGE:	20150804

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			GMS Ventures & Investments
		CENTRAL INDEX KEY:			0001804598
		ORGANIZATION NAME:           	
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
		STREET 2:		190 ELGIN AVENUE
		CITY:			GEORGE TOWN
		STATE:			E9
		ZIP:			KYI-9007
		BUSINESS PHONE:		962 6 582 7999

	MAIL ADDRESS:	
		STREET 1:		C/O INTERTRUST CORP. SVCS. (CAYMAN) LTD.
		STREET 2:		190 ELGIN AVENUE
		CITY:			GEORGE TOWN
		STATE:			E9
		ZIP:			KYI-9007
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <previousAccessionNumber>0000947871-22-000750</previousAccessionNumber>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: GMS Ventures & Investments -->
          <cik>0001804598</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>3</amendmentNo>
      <securitiesClassTitle>Common Stock, par value $0.01 per share</securitiesClassTitle>
      <dateOfEvent>01/17/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001649989</issuerCIK>
        <issuerCUSIP>69012T305</issuerCUSIP>
        <issuerName>Outlook Therapeutics, Inc.</issuerName>
        <address>
          <com:street1>111 S. Wood Avenue</com:street1>
          <com:street2>Unit #100</com:street2>
          <com:city>Iselin</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>08852</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>GMS Ventures and Investments</personName>
          <personPhoneNum>345-949-8066</personPhoneNum>
          <personAddress>
            <com:street1>c/o Maples Corporate Services Limited</com:street1>
            <com:street2>P.O Box 309 Ugland House South Church St</com:street2>
            <com:city>George Town</com:city>
            <com:stateOrCountry>E9</com:stateOrCountry>
            <com:zipCode>KY1-1104</com:zipCode>
          </personAddress>
        </notificationInfo>
        <notificationInfo>
          <personName>Allen Overy Shearman Sterling</personName>
          <personPhoneNum>713 354-4900</personPhoneNum>
          <personAddress>
            <com:street1>Bank of America Tower</com:street1>
            <com:street2>800 Capitol Street, Suite 2200</com:street2>
            <com:city>Houston</com:city>
            <com:stateOrCountry>TX</com:stateOrCountry>
            <com:zipCode>77002</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0001804598</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>GMS VENTURES &amp; INVESTMENTS</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>E9</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>12725216.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>12725216.00</sharedDispositivePower>
        <aggregateAmountOwned>12725216.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>38.6</percentOfClass>
        <typeOfReportingPerson>IV</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001717441</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>SUKHTIAN GHIATH M.</reportingPersonName>
        <memberOfGroup>b</memberOfGroup>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>M2</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>12725216.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>12725216.00</sharedDispositivePower>
        <aggregateAmountOwned>12725216.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>38.6</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock, par value $0.01 per share</securityTitle>
        <issuerName>Outlook Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>111 S. Wood Avenue</com:street1>
          <com:street2>Unit #100</com:street2>
          <com:city>Iselin</com:city>
          <com:stateOrCountry>NJ</com:stateOrCountry>
          <com:zipCode>08852</com:zipCode>
        </issuerPrincipalAddress>
        <commentText>This Amendment No. 3 ("Amendment No. 3") to Schedule 13D supplements and amends the statement on Schedule 13D of GMS Ventures and Investments ("GMS Ventures") and Ghiath M. Sukhtian ("Sukhtian" and, together with GMS Ventures, the "Reporting Persons") originally filed with the SEC on July 7, 2022, as amended by Amendment No. 1 thereto, filed with the SEC on December 29, 2022, and Amendment No. 2 thereto, filed with the SEC on March 20, 2024 (together, as so amended, the "Schedule 13D"). Except as otherwise specified in this Amendment No. 3, all items in the Schedule 13D remain unchanged. All capitalized terms used herein and not otherwise defined have the meanings ascribed to such terms in the Schedule 13D.

The Reporting Persons are filing this Amendment No. 3 to report certain changes in their beneficial ownership of Shares of the Issuer as result of GMS Ventures' execution of an Inducement Letter, as defined and described in Item 4 of this Schedule 13D.</commentText>
      </item1>
      <item2>
        <principalBusinessAddress>The principal office address of GMS Ventures is c/o Maples Corporate Services Limited, P.O Box 309, Ugland House, South Church Street, George Town, Grand Cayman KY1-1104, Cayman Islands.</principalBusinessAddress>
      </item2>
      <item3>
        <fundsSource>Item 3 of the Schedule 13D is hereby amended to add the following after the last paragraph:

The source of funds for the exercise of GMS Ventures' Existing Warrants (as defined in Item 3 below) was the working capital of GMS Ventures and capital contributions made to GMS Ventures.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>Item 4 of the Schedule 13D is hereby amended to add the following after the last paragraph:

On January 16, 2025, the Issuer entered into warrant exercise inducement offer letter agreements (each an "Inducement Letter" and together, the "Inducement Letters") with certain holders, including GMS Ventures (each a "Holder" and collectively, the "Holders"), of existing warrants to purchase Shares (the "Existing Warrants") pursuant to which the Holders agreed to exercise their Existing Warrants at a reduced exercise price of $2.51 per Share in exchange for the Issuer's agreement to issue two new warrants to purchase Shares for each Existing Warrant exercised (the "Inducement Warrants"). The transactions effected pursuant to the Inducement Letters closed on January 17, 2025.

The Inducement Warrants are exercisable at an exercise price of $2.26 per Share and are only exercisable for cash, except in limited circumstances. Half of the Inducement Warrants (the "Tranche A Inducement Warrants") are exercisable immediately and have a term of five years from the date of issuance. The remaining Inducement Warrants (the "Tranche B Inducement Warrants") will be exercisable upon the effective date (the "Amendment Effective Date") of an amendment to the Issuer's Certificate of Incorporation increasing the number of authorized Shares issuable thereunder. The Tranche B Inducement Warrants will have a term of five years from the Amendment Effective Date.

Pursuant to the terms of the Inducement Letter by and between the Issuer and GMS Ventures, GMS Ventures exercised 3,458,571 Existing Warrants at an exercise price per Share of $2.51 in return for receipt of 3,458,571 Tranche A Inducement Warrants and 3,458,571 Tranche B Inducement Warrants.</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>The following disclosure is based upon 24,905,635 outstanding Shares of the Issuer, as set forth in the Issuer's Annual Report on Form 10-Q for the year ending September 30, 2024, filed with the SEC on December 27, 2024, plus 3,458,571 Shares underlying Tranche A Inducement Warrants and 3,458,571 Shares underlying Tranche B Inducement Warrants.

As of the date hereof, GMS Ventures directly owns 5,808,074 Shares and 6,917,142 warrants to purchase Shares, representing a total of 12,725,216 Shares beneficially owned by GMS Ventures. This represents approximately 38.6% of the outstanding Shares, calculated pursuant to Rule 13d-3 under the Act.

Sukhtian is the holder of a controlling interest in GMS Holdings, which is the sole owner of GMS Ventures. By virtue of such relationship, Sukhtian may be deemed to beneficially own the securities held by GMS Ventures for purposes of Rule 13d-3 under the Act. This represents approximately 38.6% of the outstanding Shares calculated pursuant to Rule 13d-3 under the Act.</percentageOfClassSecurities>
        <numberOfShares>GMS Ventures:
1.  Sole power to vote or direct vote: 0
2.  Shared power to vote or direct vote: 12,725,216
3.  Sole power to dispose or direct the disposition: 0
4.  Shared power to dispose or direct the disposition: 12,725,216

Sukhtian:
1.  Sole power to vote or direct vote: 0
2.  Shared power to vote or direct vote: 12,725,216
3.  Sole power to dispose or direct the disposition: 0
4.  Shared power to dispose or direct the disposition: 12,725,216</numberOfShares>
        <transactionDesc>The transactions described in Item 4 are incorporated herein by reference. Except as described in Item 4, the Reporting Persons have not effected any transactions in Shares during the past sixty (60) days.</transactionDesc>
        <listOfShareholders>Not applicable.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Item 6 of the Schedule 13D is hereby amended to add the following after the last paragraph:

Inducement Letter

Item 4 above summarizes certain provisions of the Inducement Letter by and between the Issuer and GMS Ventures and is incorporated herein by reference.

Tranche A Inducement Warrants

In connection with the transactions described under Item 4 above, the Issuer agreed to file a resale registration statement on Form S-3 (the "Tranche A Resale Registration Statement") with the SEC within 45 calendar days from the execution time of the Inducement Letters to register the resale of the Shares underlying the Tranche A Inducement Warrants, and to use commercially reasonable efforts to cause the Tranche A Resale Registration Statement to become effective within 60 calendar days from the execution time of the Inducement Letters (or within 90 calendar days in case of "full review" of the Tranche A Resale Registration Statement by the SEC).

Tranche B Inducement Warrants

In connection with the transactions described under Item 4 above, the Issuer agreed to file a resale registration statement on Form S-3 (the "Tranche B Resale Registration Statement") with the SEC within 45 calendar days from the Amendment Effective Date to register the resale of the Shares underlying the Tranche B Inducement Warrants, and to use commercially reasonable efforts to cause the Tranche B Resale Registration Statement to become effective within 60 calendar days from the Amendment Effective Date (or within 90 calendar days in case of "full review" of the Tranche B Resale Registration Statement by the SEC).

The foregoing descriptions of the Inducement Letter, the Tranche A Inducement Warrants and the Tranche B Inducement Warrants do not purport to be complete and are qualified in their entirety by reference to the full text of the Inducement Letter, the Tranche A Inducement Warrants and the Tranche B Inducement Warrants, the forms of which are filed as Exhibits 5, 6 and 7 to this Amendment No. 3, respectively, and incorporated herein by reference.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>--------------------------------------------------------------------------------------------------------------------------------------
Exhibit     Description
--------------------------------------------------------------------------------------------------------------------------------------
1.             Joint Filing Agreement, between Ghiath M. Sukhtian and GMS Ventures and Investments,
                dated January 22, 2025.*
--------------------------------------------------------------------------------------------------------------------------------------
2.             Amended &amp; Restated Investor Rights Agreement by and between Outlook Therapeutics,
                Inc. and GMS Ventures and Investments, dated as of April 21, 2022 (incorporated by
                reference to Exhibit 10.1 to the Issuer's Form 8-K, filed with the SEC on April 22, 2022).
--------------------------------------------------------------------------------------------------------------------------------------
3.             Power of Attorney by Ghiath M. Sukhtian, dated as of December 30, 2019 (incorporated by
                reference to Exhibit 24.4 to the Form 4 filed by Ghiath M. Sukhtian with the SEC on
                January 29, 2020).
--------------------------------------------------------------------------------------------------------------------------------------
4.             Power of Attorney by GMS Ventures and Investments, dated as of February 25, 2020
                (incorporated by reference to Exhibit 24.1 to the Form 3 filed by GMS Ventures and
                Investments with the SEC on February 27, 2020).
--------------------------------------------------------------------------------------------------------------------------------------
5.             Form of Inducement Letter, dated as of January 16, 2025 (incorporated by reference to
                Exhibit 10.1 of to the Issuer's Form 8-K, filed with the SEC on January 16, 2025).
--------------------------------------------------------------------------------------------------------------------------------------
6.             Form of Common Stock Purchase Warrant of Outlook Therapeutics, Inc. (incorporated
                by reference to Exhibit 4.1 of to the Issuer's Form 8-K, filed with the SEC on January
                16, 2025).
--------------------------------------------------------------------------------------------------------------------------------------
7.             Form of Common Stock Purchase Warrant of Outlook Therapeutics, Inc. (incorporated by
                reference to Exhibit 4.2 of to the Issuer's Form 8-K, filed with the SEC on January 16,
                2025).
--------------------------------------------------------------------------------------------------------------------------------------

*        Filed herewith.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>GMS VENTURES &amp; INVESTMENTS</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Lawrence A. Kenyon</signature>
          <title>Lawrence A. Kenyon</title>
          <date>01/22/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>SUKHTIAN GHIATH M.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Lawrence A. Kenyon</signature>
          <title>Lawrence A. Kenyon</title>
          <date>01/22/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ss4352919_ex9901.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>JOINT FILING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">The
undersigned hereby agree that this Statement on Schedule 13D, dated January 17, 2025 (the &ldquo;<U>Schedule 13D</U>&rdquo;), with respect
to the common stock, par value $0.01 per share, of Outlook Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance
with the provisions of Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended, and that this Joint Filing Agreement (this
&ldquo;<U>Agreement</U>&rdquo;) shall be included as an Exhibit to the Schedule 13D. Each of the undersigned agrees to be responsible
for the timely filing of the Schedule 13D, and for the completeness and accuracy of the information concerning itself contained therein.
This Agreement may be executed in any number of counterparts, all of which taken together shall constitute one and the same instrument.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="background-color: white">IN
WITNESS WHEREOF, the undersigned have executed this Agreement as of the 22nd day of January, 2025.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD><FONT STYLE="font-size: 10pt">Dated: January 22, 2025</FONT></TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>GMS Ventures and Investments</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 53%">&nbsp;</TD>
    <TD STYLE="width: 3%">&nbsp;</TD>
    <TD STYLE="width: 44%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Lawrence A. Kenyon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Lawrence A. Kenyon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Attorney-in-Fact</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-size: 10pt"><B>Ghiath M. Sukhtian</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: Black 1pt solid"><FONT STYLE="font-size: 10pt">/s/ Lawrence A. Kenyon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Name: Lawrence A. Kenyon</FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-size: 10pt">Title: Attorney-in-Fact</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 1pt; margin-bottom: 1pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
